PMID- 30945457
OWN - NLM
STAT- MEDLINE
DCOM- 20200630
LR  - 20220410
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 8
IP  - 5
DP  - 2019 May
TI  - LncRNA-SNHG15 enhances cell proliferation in colorectal cancer by inhibiting 
      miR-338-3p.
PG  - 2404-2413
LID - 10.1002/cam4.2105 [doi]
AB  - The incidence and death rate of colorectal cancer (CRC) is very high, which 
      brings great need to understand the early molecular events of CRC. These studies 
      demonstrate that long noncoding RNA (lncRNA) plays an important role in the 
      occurrence and development of human cancer. Small nucleolar RNA host gene 15 
      (SNHG15) was recently identified as a cancer-related lncRNA. In this study, we 
      aimed to evaluate the function and mechanism of SNHG15 in CRC. The expression of 
      SNHG15 was detected by quantitative RT-PCR (qRT-PCR) in CRC tissues and matched 
      noncancerous tissues (NCTs). CCK-8 assay, colony formation assay, flow cytometric 
      analysis, and nude mouse xenograft mode were used to examine the tumor-promoting 
      function of SNHG15 in vitro and in vivo. The binding relationship between SNHG15, 
      miR-338-3p and the target genes of miR-338-3p were screened and identified by 
      databases, qRT-PCR, dual luciferase reporter assay and western blot. Our results 
      showed that SNHG15 was up-regulated in CRC tissues compared with paired NCTs 
      (P < 0.0001). High level of SNHG15 expression predicted poor prognosis of CRC 
      (P = 0.0051). SNHG15 overexpression could promote cell proliferation and inhibit 
      cell apoptosis. Animal experiments showed that up-regulation of SNHG15 promoted 
      tumor growth in vivo. The results of mechanism experiments showed that SNHG15 
      could bind to miR-338-3p and block its inhibition on the expression and activity 
      of FOS or RAB14. In conclusion SNHG15 promotes cell proliferation through 
      SNHG15/miR-338-3p/FOS-RAB14 axis in CRC.
CI  - (c) 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Li, Min
AU  - Li M
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
AD  - Pharmacy Department, Wuxi 9th People's Hospital Affiliated to Soochow University, 
      Wuxi, Jiangsu, China.
FAU - Bian, Zehua
AU  - Bian Z
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
FAU - Jin, Guoying
AU  - Jin G
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
FAU - Zhang, Jia
AU  - Zhang J
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
FAU - Yao, Surui
AU  - Yao S
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
FAU - Feng, Yuyang
AU  - Feng Y
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Wang, Xue
AU  - Wang X
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
FAU - Yin, Yuan
AU  - Yin Y
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
FAU - Fei, Bojian
AU  - Fei B
AD  - Department of Surgical Oncology, Affiliated Hospital of Jiangnan University, 
      Wuxi, Jiangsu, China.
FAU - You, Qingjun
AU  - You Q
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
FAU - Huang, Zhaohui
AU  - Huang Z
AUID- ORCID: 0000-0002-0117-9976
AD  - Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, 
      China.
AD  - Cancer Epigenetics Program, Wuxi School of Medicine, Jiangnan University, Wuxi, 
      Jiangsu, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190403
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (FOS protein, human)
RN  - 0 (MIRN338 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - 0 (RNA, Long Noncoding)
RN  - EC 3.6.1.- (Rab14 protein, human)
RN  - EC 3.6.5.2 (rab GTP-Binding Proteins)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Biomarkers, Tumor
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Colorectal Neoplasms/*genetics/mortality/pathology
MH  - Disease Models, Animal
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Mice
MH  - MicroRNAs/*genetics
MH  - Models, Biological
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-fos/genetics
MH  - *RNA Interference
MH  - RNA, Long Noncoding/*genetics
MH  - Xenograft Model Antitumor Assays
MH  - rab GTP-Binding Proteins/genetics
PMC - PMC6536931
OTO - NOTNLM
OT  - FOS
OT  - RAB14
OT  - colorectal cancer
OT  - long noncoding RNA
OT  - miR-338-3p
OT  - small nucleolar RNA host gene 15
COIS- The authors declare no conflict interest.
EDAT- 2019/04/05 06:00
MHDA- 2020/07/01 06:00
PMCR- 2019/04/03
CRDT- 2019/04/05 06:00
PHST- 2018/11/06 00:00 [received]
PHST- 2019/01/29 00:00 [revised]
PHST- 2019/03/06 00:00 [accepted]
PHST- 2019/04/05 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2019/04/05 06:00 [entrez]
PHST- 2019/04/03 00:00 [pmc-release]
AID - CAM42105 [pii]
AID - 10.1002/cam4.2105 [doi]
PST - ppublish
SO  - Cancer Med. 2019 May;8(5):2404-2413. doi: 10.1002/cam4.2105. Epub 2019 Apr 3.